KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Nektar Therapeutics (NKTR) Leases (2016 - 2025)

Nektar Therapeutics (NKTR) has 12 years of Leases data on record, last reported at $7.2 million in Q3 2025.

  • For Q3 2025, Leases fell 18.75% year-over-year to $7.2 million; the TTM value through Sep 2025 reached $7.2 million, down 18.75%, while the annual FY2024 figure was $8.4 million, 53.28% down from the prior year.
  • Leases reached $7.2 million in Q3 2025 per NKTR's latest filing, down from $7.6 million in the prior quarter.
  • Across five years, Leases topped out at $125.0 million in Q1 2021 and bottomed at $7.2 million in Q3 2025.
  • Average Leases over 5 years is $50.6 million, with a median of $29.0 million recorded in 2023.
  • Peak YoY movement for Leases: dropped 6.67% in 2021, then crashed 71.55% in 2023.
  • A 5-year view of Leases shows it stood at $117.0 million in 2021, then plummeted by 54.34% to $53.4 million in 2022, then plummeted by 66.3% to $18.0 million in 2023, then crashed by 53.28% to $8.4 million in 2024, then dropped by 14.76% to $7.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Leases were $7.2 million in Q3 2025, $7.6 million in Q2 2025, and $8.0 million in Q1 2025.